Challenge model for Helicobacter pylori infection in human volunteers

Gut

Volumn 53, Issue 9, 2004, Pages 1235-1243

  Graham, D Y ^a   Opekun, A R ^b   Osato, M S ^b   El Zimaity, H M T ^b   Lee, C K ^b   Yamaoka, Y ^b   Qureshi, W A ^b   Cadoz, M ^b   Monath, T P ^b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BISMUTH SALICYLATE; CARBON 13; FAMOTIDINE; INTERLEUKIN 8; METRONIDAZOLE; OMEPRAZOLE; TETRACYCLINE;

ADULT; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DYSPEPSIA; ERADICATION THERAPY; EXPERIMENTAL INFECTION; FEMALE; FOLLOW UP; GASTRITIS; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; STOMACH BIOPSY; STOMACH MUCOSA; STOMACH PH; UREA BREATH TEST;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL VACCINES; DYSPEPSIA; FEMALE; FOLLOW-UP STUDIES; GASTRIC ACIDITY DETERMINATION; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; HYDROGEN-ION CONCENTRATION; INTERLEUKINS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NONTHERAPEUTIC HUMAN EXPERIMENTATION; VIRULENCE;

EID: 4344718486     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2003.037499     Document Type: Article

References (47)

1. Miehlke S, Graham DY. Antimicrobial therapy of peptic ulcer. Int J Antimicrob Agents 1997;8:171-8.
2. Bonenfant C, Dimier-Poisson I, Velge-Roussel F, et al. Intranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protects mice against Toxoplasma gondii. Infect Immun 2001;69:1605-12.
3. Chen M, Lee A, Hazell S, et al. Immunization against gastric infection with Helicobacter species: first step in the prophylaxis of gastric cancer? Int J Med Microbiol Virol Parasitol Infect Dit 1993;280:155-65.
4. Corthesy-Theulaz IE, Hopkins S, Bachmann D, et al. Mice are protected from Helicobacter pylori infection by nasal immunization with attenuated Salmonella typhimurium phoPc expressing urease A and B subunits. Infect Immun 1998;66:581-6.
5. Czinn SJ, Nedrud JG. Oral immunization against Helicobacter pylori. Infect Immun 1991;59:2359-63.
6. Czinn SJ, Nedrud JG. Working towards a Helicobacter pylori vaccine. Gastroenterology 1999;116:990-3.
7. Del Giudice G. Towards the development of vaccines against Helicobacter pylori: status and issues. Curr Opin Invest Drugs 2001;2:40-4.
8. Ikewaki J, Nishizono A, Goto T, et al. Therapeutic oral vaccination induces mucosal immune response sufficient to eliminate long-term Helicobacter pylori infection. Microbiol Immunol 2000;44:29-39.
9. Kleanthous H, Myers GA, Georgakopoulos KM, et al. Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection. Infect Immun 1998;66:2879-86.
10. Lee CK, Soike K, Hill J, et al. Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys. Vaccine 1999;17:1493-505.
11. Satin B, Del Giudice G, Della B, V, et al. The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. J Exp Med 2000;191:1467-76.
12. Bumann D, Holland P, Siejak F, et al. A comparison of murine and human immunoproteomes of Helicobacter pylori validates the preclinical murine infection model for antigen screening. Infect Immun 2002;70:6494-8.
13. Ruggiera P, Peppoloni S, Berti D, et al. New strategies for the prevention and treatment of Helicobacter pylori infection. Expert Opin Invest Drugs 2002;11:1127-08.
14. Mukhopadhyay AK, Kersulyte D, Jeong JY, et al. Distinctiveness of genotypes of Helicobacter pylori in Calcutta, India. J Bacteriol 2000;182:3219-27.
15. Yamaoka Y, Kodama T, Kita M, et al. Relationship of vacA genotypes of Helicobacter pylori to cagA status, cytotoxin production, and clinical outcome. Helicobacter 1998;3:241-53.
16. Yamaoka Y, Kodama T, Gutierrez O, et al. Relationship between Helicobacter pylori iceA, cagA, and vacA status and clinical outcome: studies in four different countries. J Clin Microbiol 1999;37:2274-9.
17. Yamaoka Y, Orito E, Mizokami M, et al. Helicobacter pylori in North and South America before Columbus. FEBS Lett 2002;517:180-4.
18. Gerhard M, Lehn N, Neumayer N, et al. Clinical relevance of the Helicobacter pylori gene for blood-group antigen-binding adhesin. Proc Natl Acad Sci U S A 1999;96:12778-83.
19. Yamaoka Y, Kodama T, Kashima K, et al. Variants of the 3′ region of the cagA gene in Helicobacter pylori isolates from patients with different H. pyloriassociated diseases. J Clin Microbiol 1998;36:2258-63.
20. Malaty HM, Graham DY, Wattignev WA, et al. Natural history of Helicobacter pylori infection in childhood: 12-year follow-up cohort study in a biracial community. Clin Infect Dis 1999;28:279-82.
21. Genta RM, Robason GO, Graham DY. Simultaneous visualization of Helicobacter pylori and gastric morphology: a new stain. Hum Pathol 1994;25:221-6.
22. El-Zimaity HM, Ota H, Scott S, et al. A new triple stain for Helicobacter pylori suitable for the autostainer: carbol fuchsin/Alcian blue/hematoxylin- eosin. Arch Pathol Lab Med 1998;122:732-6.
23. El-Zimaity HM, Graham DY, Al-Assi MT, et al. Interobserver variation in the histopathological assessment of Helicobacter pylori gastritis. Hum Pathol 1996;27:35-41.
24. Black RE, Levine MM, Clements ML, et al. Experimental Campylobacter jejuni infection in humans. J Infect Dis 1988;157:472-9.
25. Bartelloni PJ, Tesh RB. Clinical and serologic responses of volunteers infected with phlebotomus fever virus (Sicilian type). Am J Trop Med Hyg 1976;25:456-62.
26. Tacket CO, Binion SB, Bostwick E, et al. Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge. Am J Trop Med Hyg 1992;47:276-83.
27. Mills J, Van Kirk JE, Wright PF, et al. Experimental respiratory syncytial virus infection of adults. Possible mechanisms of resistance to infection and illness. J Immunol 1971;107:123-30.
28. Hornick RB, Greisman SE, Woodward TE, et al. Typhoid fever: pathogenesis and immunologic control. 2. N Engl J Med 1970;283:739-46.
29. Sabin, AB. Research on dengue in World War II. Am J Trop Med Hyg 1952;1:30-40.
30. Tigertt WD, Benenson AS. Studies on Q fever in man. Trans Assoc Amer Phys 1956;60:98-104,
31. Marshall BJ, Armstrong JA, McGechie DB, et al. Attempt to fulfill Koch's postulates for pyloric Campylobacter. Med J Aust 1985;142:436-9.
32. Morris AJ, Ali MR, Nicholson GI, et al. Long-term follow-up of voluntary ingestion of Helicobacter pylori. Ann Intern Med 1991;114:662-3.
33. Morris A, Nicholson G. Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol 1987;82:192-9.
34. Graham DY, Alpert LC, Smith JL, et al. latrogenic Campylobacter pylori infection is a cause of epidemic achlorhydria. Am J Gastroenterol 1988;83:974-80.
35. Censini S, Lange C, Xiang Z, et al. cag, a pathogenicity island of Helicobacter pylori, encodes type l-specific and disease-associated virulence factors. Proc Natl Acad Sci U S A 1996;93:14648-53.
36. Fischer W, Puls J, Buhrdorf R, et al. Systematic mutagenesis of the Helicobacter pylori cag pathogenicity island: essential genes for CagA translocation in host cells and induction of interleukin-8. Mol Microbiol 2001;42:1337-48.
37. Yamaaka Y, Kwon DH, Graham DY. A M(r) 34,000 proinflammatory outer membrane protein (OipA) of Helicobacter pylori. Proc Natl Acad Sci USA 2000;97;7533-8.
38. Yamaaka Y, Kita M, Kodama T, et al. Helicobacter pylori infection in mice: Role of outer membrane proteins in colonization and inflammation. Gastroenterology 2002;123:1992-2004.
39. El-Zimaity HM, Al-Assi MT, Genta RM, et al. Confirmation of successful therapy of Helicobacter pylori infection: number and site of biopsies or a rapid urease test. Am J Gastroenterol 1995;90:1962-4.
40. Woo JS, El-Zimaity HM, Genta RM, et al. The best gastric site for obtaining a positive rapid urease test. Helicobacter 1996;1:256-9.
41. Genta RM, Graham DY. Comparison of biopsy sites for the histopathologic diagnosis of Helicobacter pylori: a topographic study of H. pylori density and distribution. Gastrointest Endosc 1994;40:342-5.
42. El-Zimaity HM, Graham DY. Evaluation of gastric mucosal biopsy site and number for identification of Helicobacter pylori or intestinal metaplasia: role of the Sydney system. Hum Pathol 1999;30:72-7.
43. Leung WK, Siu KL, Kwok CK, et al. Isolation of Helicobacter pylori from vomitus in children and its implication in gastro-oral transmission. Am J Gastroenterol 1999;94:2881-4.
44. Personnet J, Shmuely H, Haggerty T. Fecal and oral shedding of Helicobacter pylori from healthy infected adults. JAMA 1999;282:2240-5.
45. Blanchard TG, Lycke N, Czinn SJ, et al. Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral immunization of mice against Helicobacter felis. Immunology 1998;94:22-7.
46. Lee CK, Weltzin R, Thomas WD Jr, et al. Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J Infect Dis 1995;172:161-72.
47. Weltzin R, Kleanthous H, Guirakhoo F, et al. Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection. Vaccine 1997;15:370-6.